PhaseBio Pharmaceuticals, Inc. Initiated Phase 1 Study of Investigational Once-Weekly Basal Insulin for Potential Treatment of Diabetes

Published: Jun 04, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MALVERN, Pa.--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company focused on diabetes and cardiovascular diseases, today announced that it has initiated the first Phase 1 study for development of PE0139, a novel long-acting basal insulin, for the treatment of Type 2 diabetes.

Help employers find you! Check out all the jobs and post your resume.

Back to news